Concepedia

Brent McHenry

BM

Statistics

Publications

8

Citations

304

H-Index

8

Active since

2007

Affiliations

Bristol-Myers Squibb (United States)(Current)

Memorial Sloan Kettering Cancer Center

The University of Texas MD Anderson Cancer Center

Mayo Clinic in Arizona

Oregon Health & Science University

Brent McHenry is an author at Bristol-Myers Squibb (United States) specializing in medicine, oncology, and pharmacology.

Publications per year

2007–2020

8

Publications

8

Phase II Clinical Trial of the Epothilone B Analog, Ixabepilone, in Patients With Non–Small-Cell Lung Cancer Whose Tumors Have Failed First-Line Platinum-Based Chemotherapy

Johan Vansteenkiste, Primo N. Lara, Thierry Le Chevalier et al. · Journal of Clinical Oncology · 2007 · 129 citations

, , +13

Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).

Robert J. Motzer, Toni K. Choueiri, David F. McDermott et al. · Journal of Clinical Oncology · 2020 · 44 citations

, , +17

Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC)

H. S. Rugo, Mario Campone, D. Amadori et al. · Journal of Clinical Oncology · 2009 · 42 citations

, , +14

A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914).

Axel Bex, Paul Russo, Yoshihiko Tomita et al. · Journal of Clinical Oncology · 2020 · 23 citations

, , +16

Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials.

Célèste Lebbé, Jeffrey S. Weber, Michele Maio et al. · Journal of Clinical Oncology · 2013 · 20 citations

, , +17

1–5 of 8